期刊文献+

重组人钙网蛋白的克隆与原核表达 被引量:1

Cloning and Prokaryotic Expression of Human Recombinant Calreticulin
下载PDF
导出
摘要 目的:克隆人钙网蛋白(calreticulin,CRT)并进行原核表达和纯化。方法:采用RT-PCR法从人非小细胞肺腺癌A549细胞总RNA中克隆人钙网蛋白cDNA,构建CRT原核表达质粒(pE15b/CRT)并转化E.coli的Rossetta菌株。IPTG诱导后,表达蛋白在变性条件下经Ni-NTA树脂亲和层析纯化,然后透析复性。分别用SDS-PAGE和Western blotting鉴定CRT表达和纯化状态结果:从A549细胞总RNA中成功获得人CRTcDNA克隆,重组质粒pET-15b/CRT构建正确。转化pET-15b/CRT的E.coliRossetta诱导性表达重组人CRT蛋白,该蛋白可经Ni-NTA树脂亲和层析高度纯化。结论:成功建立了CRT原核表达和纯化的实验方法,该方法为后续的CRT蛋白功能研究奠定了基础。 Objective: Clone, express and purify human recombinant calreticulin (CRT). Methods: Human CRT cDNA was amplified from total RNA of human lung cancer cell line A549 ceils by RT-PCR. Then, PCR product was subcloned into prokaryotic expression vector pET-15b. After sequencing, this recombinant plasmid was transformed into E. coli. Rossetta. Recombinant CRT was expressed in host ceils by IPTG induction. Resulted protein was purified by Ni-NTA resin under denature condition and dialyzed to recover its native structure. SDS- PAGE and Western blot method were used to identify the expression and purification of reconbinant CRT. Results: Human CRT cDNA was cloned from total RNA of A549 ceils. CRT prokaryotic expression vector pET-15b-crt was constructed. Reconbinant CRT was induced to express in E. coli and purified by Ni-NTA affinity chromatograph. Conclusion: A method for prokaryotic expression and purification of human recombinant CRT was successfully established. This method laid a foundation for the subsequent CRT research.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2008年第4期70-73,共4页 China Biotechnology
基金 国家自然科学基金资助项目(30772590)
关键词 钙网蛋白 原核表达 蛋白纯化 Calreticulin Prokaryotic expression Protein purification
  • 相关文献

参考文献8

  • 1Arosa A, de Jesus O, Porto G, et al. Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibillty complex Ⅰ molecules. Biol Chem, 1999,274 : 16917 - 16922
  • 2Lewis J W, Elllott T. Evidence for successive peptide binding and quality control stages during MHC class Ⅰ assembly. Curr Biol, 1998, 8:717-720
  • 3Fraser S A, Karimi R, Michalak M, et al. Perforin lytic activity is controlled by calreticulin. Immunol,2000,164:4150 -4155
  • 4Mery L, Mesaell N, Michalak M, et al.Overexpression of calreficulin increases intracellular Ca^2 + storage and decreases store-operated Ca^2 + influx. Biol Chem, 1996, 271 : 9332 - 9339
  • 5Burns K, Duggan B, Atkinson E A, et al. Modulation of gene expression by calreticulin binding to the glucocorticoid receptor. Nature, 1994, 367:476-480
  • 6Gardai S J, Kathleen A, Henson P M, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell, 2005, 123 : 321 -334
  • 7Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med, 2007, 13(1 ) :54 -61
  • 8Coppolino M G, Dedhar S. Calreticulin . Biochemistry & Cell Biology, 1998, 30:553 - 558

同被引文献6

  • 1Arosa A, de Jesus O, Porto G, et al. Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex I molecules[ J]. J Biol Chem, 1999, 274: 16917- 16922.
  • 2Lewis JW, Elliott T. Evidence for successive peptide binding and quality control stages during MHC class I assembly [ J ]. Curr Biol, 1998, 8:717 -720.
  • 3Fraser SA, Karimi R, Michalak M, et al. Perforin lytic activity is controlled by calreticulin [ J ]. Immunology, 2000, 164: 4150 -4155.
  • 4Gardai SJ, Kathleen A, Henson PM, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte[J].Cell, 2005, 123:321 -334.
  • 5Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death [ J ]. Nat Med, 2007, 13(1) :54 -61.
  • 6Coppolino MG, Dedhar S. Calreticulin [ J]. Biochem Cell Biol, 1998, 30:553 -558.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部